Inactive Instrument

US Rare Earth Minerals Inc Share Price Other OTC

US9034101082

Biotechnology & Medical Research

End-of-day quote Other OTC
- ^USD	-

15/08	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
11/08	Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID	CI

Valuation : US Rare Earth Minerals Inc

Market Cap	26.56L 22.89L 21.67L 19.64L 36.85L 25Cr 37.04L 2.57Cr 98.98L 13Cr 99.76L 97.57L 41Cr	P/E 2024	-5.27x	P/E 2025	-3.28x
Enterprise Value	33.97L 29.27L 27.71L 25.12L 47.13L 32Cr 47.37L 3.29Cr 1.27Cr 17Cr 1.28Cr 1.25Cr 52Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.38%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : US Rare Earth Minerals Inc

15/08	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
11/08	Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID	CI
04/08	Bioxytran, Inc. and University Of Minnesota Department Of Chemistry Execute Second Sponsored Research Agreement To Advance ASI-Powered Carbohydrate Drug Design Platform	CI
31/07	US officials pressed China on rare earths, farm goods commitments, Bessent says	RE
29/07	Bioxytran Announces Publication of Corporate Research Report Discussing Prolectin-M Phase 2 Results, Planned 408-Patient Registrational Trial, Bxt-25 Oxygen-Therapeutic Platform, and A-Suqar Commercial Distribution Agreement	CI
16/07	Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst	RE
15/05	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	CI
18/03	Bioxytran, Inc. announced that it has received $1.158942 million in funding	CI
05/03	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
02/03	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19	RE
17/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement	CI

More news

Press Releases : US Rare Earth Minerals Inc

11/08	Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence	AQ
04/08	Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs	AQ
29/07	Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research	AQ
29/05	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25	AQ
20/03	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT	AQ

More press releases

Managers and Directors : US Rare Earth Minerals Inc

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	01/09/2018
Ola Soderquist DFI	Director of Finance/CFO	65	01/09/2018
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	02/11/2018
Alan Hoberman BRD	Director/Board Member	73	02/11/2018
David Platt CHM	Chairman	73	01/09/2018

More insiders

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-2.11%	-1.68%	+44.52%	+95.15%	6.69TCr
ARGENX SE	-0.23%	-4.45%	+30.39%	+73.64%	6.2TCr
INSMED INCORPORATED	+1.67%	+2.47%	-11.23%	+388.34%	2.83TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-4.43%	+30.56%	+10.07%	2.46TCr
BIONTECH SE	+0.34%	-6.78%	-7.27%	-17.99%	2.43TCr
GENMAB A/S	+0.43%	-3.37%	+14.85%	-19.29%	1.94TCr
PHARMAESSENTIA CORPORATION	-3.03%	-2.29%	+185.12%	+334.07%	1.68TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-4.94%	-5.29%	+495.65%	1.42TCr
EXELIXIS, INC.	-2.28%	-4.90%	+43.64%	+155.21%	1.39TCr
Average	-0.91%	-3.46%	+36.14%	+168.32%	3TCr
Weighted average by Cap.	-0.84%	-3.06%	+33.46%	+133.67%

	2024	2025
Net sales	-	-
Net income	-23.67L -20.39L -19.31L -17.5L -32.83L -23Cr -33L -2.29Cr -88.18L -12Cr -88.88L -86.93L -36Cr	-21.23L -18.29L -17.32L -15.7L -29.45L -20Cr -29.6L -2.06Cr -79.11L -10Cr -79.73L -77.98L -33Cr
Net Debt	10.89L 9L 9L 8L 15.11L 10Cr 15.18L 1.06Cr 40.57L 5.29Cr 40.9L 40L 17Cr	7L 6L 6L 5L 10.28L 7.08Cr 10.33L 71.77L 27.6L 3.6Cr 27.82L 27.21L 11Cr

US Rare Earth Minerals Inc Share Price Other OTC

Stocks

US9034101082

Biotechnology & Medical Research

Valuation : US Rare Earth Minerals Inc

Latest news : US Rare Earth Minerals Inc

Press Releases : US Rare Earth Minerals Inc

Managers and Directors : US Rare Earth Minerals Inc

Bio Therapeutic Drugs

Financials

Company Profile